# EDGAR Filing Document

**Accession Number:** 0001959742
**File Stem:** 0001209191-23-002775
**Filing Date:** 2023-1
**Character Count:** 10843
**Document Hash:** 753a7401671d60d90697a88234ee90cf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-002775.hdr.sgml**: 20230110

**ACCESSION NUMBER**: 0001209191-23-002775

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230101

**FILED AS OF DATE**: 20230110

**DATE AS OF CHANGE**: 20230110

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Shook David
- **CENTRAL INDEX KEY:** 0001959742

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39370
- **FILM NUMBER:** 23521293

**MAIL ADDRESS:**
- **STREET 1:** 6000 SHORELINE COURT, SUITE 102
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nkarta, Inc.
- **CENTRAL INDEX KEY:** 0001787400
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 474515206
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 6000 SHORELINE COURT
- **STREET 2:** SUITE 102
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 415-582-4923

**MAIL ADDRESS:**
- **STREET 1:** 6000 SHORELINE COURT
- **STREET 2:** SUITE 102
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

## Ex-24

```

POWER OF ATTORNEY
FOR SEC FILINGS ON FORMS ID, 3, 4, 5 AND 144

The undersigned hereby constitutes and appoints each of Paul Hastings, Chief
Executive Officer, and Alicia Hager, JD, PhD, Chief Legal Officer, of Nkarta,
Inc., a Delaware corporation (the "Company"), so long as each is employed at the
Company, and C. Brophy Christensen and Regina Braman, each of O'Melveny & Myers
LLP ("OMM"), outside counsel to the Company, so long as each is employed at OMM,
as his true and lawful attorney-in-fact and agent (each, an "Attorney-In-Fact"),
with full power of substitution and resubstitution for him and in his name and
stead in any and all capacities, to sign and file for and on his behalf, in
respect of any acquisition, disposition or other change in ownership of any of
the securities of the undersigned, the following:

(i) 	any Form ID to be filed with the Securities and Exchange Commission (the
"SEC");
(ii)	any Update Passphrase Request to be filed with the SEC;
(iii)	any Initial Statement of Beneficial Ownership of Securities on Form 3 to
be filed with the SEC;
(iv)	any Statement of Changes of Beneficial Ownership of Securities on Form 4 to
be filed with the SEC;
(v)	any Annual Statement of Beneficial Ownership of Securities on Form 5 to be
filed with the SEC;
(vi)	any Notice of Proposed Sale of Securities on Form 144 to be filed with the
SEC; and
(vii)	any and all agreements, certificates, receipts, or other documents in
connection therewith.

The undersigned hereby gives full power and authority to each Attorney-In-Fact
to seek and obtain as his representative and on his behalf, information on
transactions in the securities of the undersigned from any third party,
including brokers, employee benefit plan administrators and trustees, and the
undersigned hereby authorizes any such third party to release such information
to each Attorney-In-Fact and approves and ratifies any such release of
information.

The undersigned hereby grants unto each Attorney-In-Fact full power and
authority to do and perform each and every act and thing requisite and necessary
in connection with such matters and hereby ratifies and confirms all that any
such Attorney-In-Fact or substitute may do or cause to be done by virtue hereof.

The undersigned acknowledges that:

(i)	neither the Company nor any Attorney-In-Fact assumes (i) any liability for
the undersigned's responsibility to comply with the requirement of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), (ii) any
liability of the undersigned for any failure to comply with such requirements or
(iii) any obligation or liability of the undersigned for profit disgorgement
under Section 16(b) of the Exchange Act; and
(ii)	this Power of Attorney does not relieve the undersigned from responsibility
for compliance with the undersigned's obligations under the Exchange Act,
including without limitation the reporting requirements under Section 16 of the
Exchange Act.

This Power of Attorney shall remain in full force and effect with respect to the
undersigned until revoked by the undersigned in a signed writing delivered to
each Attorney-In-Fact.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.]

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 21st day of December, 2022.

/s/ DAVID SHOOK
____________________

DAVID SHOOK

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Shook David<br><sub>(Last) (First) (Middle)</sub><br>C/O NKARTA, INC.<br>6000 SHORELINE COURT, SUITE 102<br><sub>(Street)</sub><br>SOUTH SAN FRANCISCO, CA 94080<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Nkarta, Inc. [ NKTX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-01-01 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Medical Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 22977<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | <sup>(2)</sup> | 2030-07-08 | Common Stock | 13300 | $18.00 | D |  |
| Stock Option (right to buy) | <sup>(3)</sup> | 2030-07-08 | Common Stock | 4300 | $18.00 | D |  |
| Stock Option (right to buy) | <sup>(4)</sup> | 2030-07-08 | Common Stock | 4800 | $18.00 | D |  |
| Stock Option (right to buy) | <sup>(5)</sup> | 2031-01-07 | Common Stock | 4680 | $54.89 | D |  |
| Stock Option (right to buy) | <sup>(6)</sup> | 2031-04-29 | Common Stock | 150 | $31.85 | D |  |
| Stock Option (right to buy) | <sup>(7)</sup> | 2032-01-13 | Common Stock | 3310 | $12.14 | D |  |
| Stock Option (right to buy) | <sup>(8)</sup> | 2032-04-28 | Common Stock | 5000 | $18.44 | D |  |
| Stock Option (right to buy) | <sup>(9)</sup> | 2032-05-15 | Common Stock | 7000 | $13.86 | D |  |
| Stock Option (right to buy) | <sup>(10)</sup> | 2032-06-16 | Common Stock | 35000 | $12.25 | D |  |
| Stock Option (right to buy) | <sup>(11)</sup> | 2032-08-19 | Common Stock | 30000 | $16.46 | D |  |

---

### Footnotes:

(1) Includes 1,660 Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2023, 5,000 RSUs which vest in four equal annual installments beginning on June 17, 2023, and 15,000 RSUs which vest in four equal annual installments beginning on August 20, 2023. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

(2) The option is vested and exercisable as to 8,589 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on June 1, 2024.

(3) The option is vested and exercisable as to 2,687 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on July 1, 2024.

(4) The option is vested and exercisable as to 3,000 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on July 9, 2024.

(5) The option is vested and exercisable as to 2,340 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on January 8, 2025.

(6) The option is vested and exercisable as to 62 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on April 30, 2025.

(7) The option is vested and exercisable as to 759 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on January 14, 2026.

(8) The option is vested and exercisable as to 833 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on April 29, 2026.

(9) The option is vested and exercisable as to 1,021 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on May 16, 2026.

(10) The option is vested and exercisable as to 4,375 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on June 17, 2026.

(11) The option is vested and exercisable as to 2,500 shares, and the remaining shares will vest and become exercisable ratably in monthly installments until fully vested on August 20, 2026.

**Signature:** /s/ Alicia Hager, as Attorney-in-Fact  
**Date:** 2023-01-10

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**